BRIDGEWATER, N.J., Nov. 8, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (SVNT) today reported financial results for the three and nine months ended September 30, 2012, which reflects the Company’s continuing commercialization of KRYSTEXXA ® (pegloticase) in the U.S. Savient ended the quarter with approximately $116.2 million in cash and short-term investments.
